ADC Therapeutics SA.
- ADCT · NYSE
- Pharmaceutical Preparations
- Epalinges, V8
- CIK 0001771910
Updated from SEC filings through
Top things to know
Executives
-
Ameet Mallik Chief Executive Officer of ADC Therapeutics 8-K, November 4, 2026 -
Jose Carmona Chief Financial Officer Form 4, July 2, 2026 -
Mohamed Zaki MD, PhD, Chief Medical Officer of ADC Therapeutics 8-K, November 4, 2026 -
Peter J. Graham Chief Legal Officer Form 4, July 2, 2026 - Lisa Kallebo Corporate Controller and Chief Accounting Officer 10-K, March 10, 2026
What leadership is saying
“During the third quarter, we made meaningful progress toward strengthening ADC Therapeutics' balance sheet and increasing strategic optionality while advancing clinical opportunities for ZYNLONTA®”
Earnings press release (8-K Ex. 99.1), filed November 9, 2026
ADC Therapeutics SA is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Epalinges, V8. It trades as ADCT on NYSE. Revenue was $81.4M in the fiscal year ending December 31, 2025, +14.9% from the year before. Ameet Mallik is Chief Executive Officer of ADC Therapeutics.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $81.4M 10-K, 2026-03-10 | $70.8M 10-K, 2026-03-10 | $69.6M 10-K, 2025-03-27 | $210M 10-K, 2024-03-13 | Not on file |
| Operating income | -$121M 10-K, 2026-03-10 | -$131M 10-K, 2026-03-10 | -$166M 10-K, 2025-03-27 | -$123M 10-K, 2024-03-13 | -$262M 20-F, 2023-03-15 |
| SG&A | $79.9M 10-K, 2026-03-10 | $85.9M 10-K, 2026-03-10 | $106M 10-K, 2025-03-27 | $143M 10-K, 2024-03-13 | Not on file |
| Net income | -$143M 10-K, 2026-03-10 | -$158M 10-K, 2026-03-10 | -$240M 10-K, 2025-03-27 | -$157M 10-K, 2024-03-13 | -$230M 20-F, 2023-03-15 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| President and CEO | Chief Executive Officer of ADC Therapeutics | 8-K, November 4, 2026 |
| | Chief Financial Officer | Form 4, July 2, 2026 |
| Chief Medical Officer, SVP at ADC Therapeutics | MD, PhD, Chief Medical Officer of ADC Therapeutics | 8-K, November 4, 2026 |
| | Chief Legal Officer | Form 4, July 2, 2026 |
| Lisa Kallebo | Corporate Controller and Chief Accounting Officer | 10-K, March 10, 2026 |
| Jean-Pierre Bizzari, M.D. | Board member (per proxy) bio: member of our board of directors | DEF 14A, April 20, 2026 |
| Timothy Coughlin, CPA | Board member (per proxy) bio: member of our board of directors | DEF 14A, April 20, 2026 |
| Ron Squarer | Chairman of the Board of Directors | 10-K, March 10, 2026 |
| Peter Hug | Director | 10-K, March 10, 2026 |
| Robert Azelby | Director | 10-K, March 10, 2026 |
| Tyrell Rivers | Director | 10-K, March 10, 2026 |
| Victor Sandor | Director | 10-K, March 10, 2026 |
| Viviane Monges | Director | 10-K, March 10, 2026 |
What ADC Therapeutics SA does
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC.S. Food and Drug Administration (“FDA”) and conditional approval from the European Commission, China National Medical Products Administration (“NMPA”) and Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 127.7 million (as of August 3, 2026) | 10-Q, August 13, 2026 |
|---|---|---|
| Public float | $136M (as of June 30, 2025) | 10-K, March 10, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 9, 2026 |
| Latest proxy statement | Meeting June 1, 2026 (filed April 20, 2026) | DEF 14A, April 20, 2026 |
| Auditor | PricewaterhouseCoopers SA (Lausanne, Switzerland) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-11-09
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-10-13
- Item 1.01 Entry into a material definitive agreement
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2026-08-13
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-07-02
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-06-24
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-06-03
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-06-02
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-10
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about ADC Therapeutics SA
- What does ADC Therapeutics SA do?
- In its own words, from Item 1 of its 10-K: "ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (“ADCs”), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC.S. Food and Drug Administration (“FDA”) and conditional approval from the European Commission, China National Medical Products Administration (“NMPA”) and Health Canada for the treatment of relapsed or refractory DLBCL after two or more lines of systemic therapy."
- What is ADC Therapeutics SA's revenue?
- $81.4M for the fiscal year ending December 31, 2025, from its 10-K filed March 10, 2026.
- Is ADC Therapeutics SA profitable?
- ADC Therapeutics SA reported net income of -$143M for the fiscal year ending December 31, 2025.
- Who is the CEO of ADC Therapeutics SA?
- Ameet Mallik, Chief Executive Officer of ADC Therapeutics, as named in a 8-K filed November 4, 2026.
- Who is the CFO of ADC Therapeutics SA?
- Jose Carmona, Chief Financial Officer, as named in a 4 filed July 2, 2026.
- Where is ADC Therapeutics SA headquartered?
- Epalinges, V8.
- What is ADC Therapeutics SA's stock ticker?
- ADCT on NYSE.
- What industry is ADC Therapeutics SA in?
- Pharmaceutical Preparations, SIC code 2834.
- What is ADC Therapeutics SA's website?
- adctherapeutics.com.
- When does ADC Therapeutics SA report earnings next?
- January 4, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is ADC Therapeutics SA a public company?
- Yes. ADC Therapeutics SA files with the SEC under CIK 0001771910 and trades as ADCT.
- Who audits ADC Therapeutics SA?
- PricewaterhouseCoopers SA, Lausanne, Switzerland, as named in its latest annual report (10-K).
- How many shares of ADC Therapeutics SA are outstanding?
- 127.7 million shares as of August 3, 2026, from its 10-Q filed August 13, 2026.
- What is ADC Therapeutics SA's public float?
- $136M as of June 30, 2025, as reported on the cover of its 10-K filed March 10, 2026.
- How many business segments does ADC Therapeutics SA report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 9, 2026.
- When is ADC Therapeutics SA's annual shareholder meeting?
- June 1, 2026, per its proxy statement (DEF 14A) filed April 20, 2026.